Clinical Cancer Research · 2006 · 21 citations · 27 references
Life SciencesImmunologyOncologyApoptosisCancer ImmunologyImmunopathologyT Cell BiologyTumor-infiltrating LymphocytesAnnexin V AssaysCd4+ Tumor-infiltrating LymphocytesCd8 Positive T CellsCd8 T Cell ActivationCd8+ Tumor-infiltrating LymphocytesControlsFlow Cytometry AntibodiesFlow Cytometry Immunophenotyping
PURPOSE: Apoptosis of activated CD8(+) T cells is often seen in tumor-infiltrating lymphocytes and circulating peripheral blood mononuclear cells (PBMC) in patients with squamous cell carcinoma of the head and neck (SCCHN). We investigated whether T-cell receptor (TCR) variable beta chain (Vbeta)-restricted T cells were more sensitive to apoptosis than non-TCR Vbeta-restricted T cells. EXPERIMENTAL DESIGN: Flow cytometry analysis with anti-TCR Vbeta antibodies was used to define expansions and contractions of Vbeta-restricted T cells in patients with SCCHN relative to normal donors. This staining was combined with Annexin V binding to indicate early T-cell apoptosis. RESULTS: The TCR Vbeta profiles of CD3(+) T cells in tumor-infiltrating lymphocytes and PBMCs of patients with SCCHN were altered relative to controls, with one to five expansions and numerous contractions of TCR Vbeta-restricted T cells detected. These types of alterations were significantly greater in CD8(+) than CD4(+) T cells. Enhanced Annexin V binding to CD8(+) T cells was evident in PBMCs obtained from all patients, with 3 of 13 showing preferential targeting for apoptosis of TCR Vbeta-restricted T cells. CONCLUSIONS: TCR Vbeta profiles of CD8(+) T cells were altered in patients with SCCHN relative to normal controls. This may reflect increased apoptosis of expanded or contracted CD8(+) T cells, which define the TCR Vbeta profile of antigen-responsive T-cell populations in patients with cancer.
27
Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma
Nikhil Yawalkar, Katalin Ferenczi, David A. Jones et al. · Blood · 2003 · 172 citations · Full text
Life Sciences, Immunology, Oncology +16